The clear relationship between NF-κB and PD-L1 expression in cancers has prompted the idea that perhaps siRNA-mediated NF-κB silencing or pharmacological inhibitors of NF-κB could be used as potential therapeutics [108]. This evidence concerns the gene CD274 and cancer.